Cargando…

ABCG2 Overexpression Contributes to Pevonedistat Resistance

MLN4924 (pevonedistat) is a first-in-class NEDD8-activating enzyme (NAE) inhibitor in clinical trials for the treatment of solid tumors and hematologic malignancies. Despite the promising activity of MLN4924 observed in early trials, drug resistance has been noted in some patients. Identifying the u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kathawala, Rishil J., Espitia, Claudia M., Jones, Trace M., Islam, Shariful, Gupta, Pranav, Zhang, Yun-Kai, Chen, Zhe-Sheng, Carew, Jennifer S., Nawrocki, Steffan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072604/ https://www.ncbi.nlm.nih.gov/pubmed/32059437 http://dx.doi.org/10.3390/cancers12020429

Ejemplares similares

Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
por: Jones, Trace M., et al.
Publicado: (2019)

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
por: Islam, Shariful, et al.
Publicado: (2021)

WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells
por: Zhang, Hui, et al.
Publicado: (2014)

Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism
por: Jones, Trace M., et al.
Publicado: (2022)

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020)

Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity
por: Jones, Trace M., et al.
Publicado: (2023)

A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo
por: Anreddy, Nagaraju, et al.
Publicado: (2015)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer
por: Jones, Trace M., et al.
Publicado: (2021)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
por: Wang, Yi-Jun, et al.
Publicado: (2014)

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
por: Carew, Jennifer S., et al.
Publicado: (2017)

Multidrug resistance associated proteins in multidrug resistance
por: Sodani, Kamlesh, et al.
Publicado: (2012)

Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs
por: Kathawala, Rishil J., et al.
Publicado: (2014)

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
por: Mahalingam, Devalingam, et al.
Publicado: (2019)

Correction: The Chemoprevention of Ovarian Cancer: the Need and the Options
por: Kathawala, Rishil J., et al.
Publicado: (2018)

The Chemoprevention of Ovarian Cancer: the Need and the Options
por: Kathawala, Rishil J., et al.
Publicado: (2018)

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance
por: Nawrocki, Steffan T., et al.
Publicado: (2020)

ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma
por: Carew, Jennifer S., et al.
Publicado: (2012)

Autophagy as a target for cancer therapy: new developments
por: Carew, Jennifer S, et al.
Publicado: (2012)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Y(6), an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance
por: Zhao, Rui-Qiang, et al.
Publicado: (2019)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020)

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents
por: Zhang, Yun-Kai, et al.
Publicado: (2015)

ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel
por: Kathawala, Rishil J, et al.
Publicado: (2015)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
por: KATHAWALA, RISHIL J., et al.
Publicado: (2014)

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
por: Carew, Jennifer S, et al.
Publicado: (2008)

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018)

Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)
por: DENG, WEN, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cd8s91hj6qbebcuh1u997umrob